KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

AbCellera Biologics (ABCL) Return on Sales (2020 - 2026)

AbCellera Biologics filings provide 7 years of Return on Sales readings, the most recent being 0.05% for Q1 2026.

  • Quarterly Return on Sales rose 6.0% to 0.05% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 0.02% through Mar 2026, up 5.0% year-over-year, with the annual reading at 0.02% for FY2025, 4.0% up from the prior year.
  • Return on Sales hit 0.05% in Q1 2026 for AbCellera Biologics, down from 0.0% in the prior quarter.
  • Across five years, Return on Sales topped out at 0.01% in Q1 2022 and bottomed at 0.11% in Q1 2025.
  • Average Return on Sales over 5 years is 0.04%, with a median of 0.04% recorded in 2024.
  • Peak annual rise in Return on Sales hit 7bps in 2025, while the deepest fall reached -7bps in 2025.
  • AbCellera Biologics' Return on Sales stood at 0.01% in 2022, then crashed by -270bps to 0.05% in 2023, then crashed by -32bps to 0.07% in 2024, then soared by 97bps to 0.0% in 2025, then crashed by -2503bps to 0.05% in 2026.
  • Per Business Quant, the three most recent readings for ABCL's Return on Sales are 0.05% (Q1 2026), 0.0% (Q4 2025), and 0.06% (Q3 2025).